Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis
出版年份 2021 全文链接
标题
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis
作者
关键词
Urothelial carcinoma, Immunotherapy, Programmed cell death ligand 1, Meta-analysis, Immune checkpoint inhibitors
出版物
European Urology Focus
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-01-27
DOI
10.1016/j.euf.2021.01.003
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel immunotherapy combinations for genitourinary cancers
- (2020) Munjid Al Harthy et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors
- (2020) Veronica Mollica et al. Expert Review of Anticancer Therapy
- Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
- (2020) Veronica Mollica et al. Cancers
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of metastatic bladder cancer
- (2019) Rosa Nadal et al. CANCER TREATMENT REVIEWS
- The Clinical Significance of Soluble PD-1 and PD-L1 in Lung Cancer
- (2019) Taher Abu Hejleh et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunotherapy and urothelial carcinoma: An overview and future prospectives
- (2019) Francesco Pierantoni et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma
- (2018) Anjelica Hodgson et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Immunotherapy Advances in Urothelial Carcinoma
- (2018) Rohit K Jain et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
- (2018) Daniel L. Suzman et al. ONCOLOGIST
- Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer
- (2018) Viktoria Stühler et al. WORLD JOURNAL OF UROLOGY
- Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions
- (2018) Abhishek Tripathi et al. Current Urology Reports
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression
- (2017) Maria Tretiakova et al. MODERN PATHOLOGY
- Pembrolizumab is superior to chemotherapy
- (2017) Peter Sidaway Nature Reviews Urology
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base
- (2013) Angela B. Smith et al. BJU INTERNATIONAL
- Cisplatin-Ineligible and Chemotherapy-Ineligible Patients Should Be the Focus of New Drug Development in Patients With Advanced Bladder Cancer
- (2013) Guru Sonpavde et al. Clinical Genitourinary Cancer
- Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma
- (2011) M. D. Galsky et al. ANNALS OF ONCOLOGY
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
- (2011) Matthew D Galsky et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now